Actively Recruiting

Phase 3
Age: 18Years +
All Genders
NCT07094087

Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)

Led by CSL Behring · Updated on 2026-05-11

200

Participants Needed

18

Research Sites

65 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a phase 3, multicenter, randomized, open-label, parallel-group, controlled study to assess the efficacy and safety of BE1116 compared with fresh frozen plasma (FFP) in adult participants undergoing complex cardiovascular surgery with CPB. The primary purpose of the study is to compare the efficacy of BE1116 and FFP in correcting coagulation factor deficiencies in bleeding participants undergoing complex cardiovascular surgery with CPB.

CONDITIONS

Official Title

Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 years or older who have provided written informed consent
  • Undergoing elective complex cardiovascular surgery requiring cardiopulmonary bypass, including thoracic aorta procedures (with or without additional cardiac interventions), aortic valve replacement with coronary artery bypass graft, complex valve surgeries, mitral valve repair with bypass graft, mitral valve replacement with bypass graft, or reoperative coronary artery bypass graft
  • Coagulation factor replacement (4F-PCC or FFP) ordered during surgery to manage bleeding
  • INR of 1.6 or higher measured 5 to 10 minutes after protamine infusion for heparin reversal
  • Significant microvascular bleeding with a bleeding severity score of 2 or higher, not due to surgical complications
Not Eligible

You will not qualify if you...

  • Received any systemic hemostatic therapy such as cryoprecipitate, platelets, FFP, PCC (4F-PCC or 3F-PCC), FEIBA, recombinant activated Factor VIIa, or other coagulation factor products within 24 hours before surgery, except when FFP is added to the cardiopulmonary bypass circuit
  • Undergoing heart transplantation
  • Undergoing insertion or removal of ventricular assist devices (except intra-aortic balloon pumps)
  • Undergoing acute repair of thoracoabdominal aneurysms

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 18 locations

1

UCLA Health - Ronald Reagan Medical Center

Los Angeles, California, United States, 90095

Actively Recruiting

2

University of Chicago Medicine

Chicago, Illinois, United States, 60637

Not Yet Recruiting

3

University of Maryland Medical Center (UMMC)

Baltimore, Maryland, United States, 21201

Actively Recruiting

4

North Shore University Hospital

Manhasset, New York, United States, 11040

Not Yet Recruiting

5

University of Cincinnati

Cincinnati, Ohio, United States, 45267

Actively Recruiting

6

OUHSC (University of Oklahoma Health Sciences Center)

Oklahoma City, Oklahoma, United States, 73104

Actively Recruiting

7

Oregon Health & Sciences University

Portland, Oregon, United States, 97239

Actively Recruiting

8

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, United States, 19107

Actively Recruiting

9

UT Southwestern Medical Center

Dallas, Texas, United States, 75390

Not Yet Recruiting

10

University of Virginia Health System

Charlottesville, Virginia, United States, 22908

Not Yet Recruiting

11

Kingston Health Science Center

Kingston, Ontario, Canada, K7L 2V7

Not Yet Recruiting

12

London Health Sciences Center - University Campus

London, Ontario, Canada, N6A 5A5

Actively Recruiting

13

University of Toronto - St. Michael's Hospital (SMH) - Keenan Research Centre for Biomedical Science

Toronto, Ontario, Canada, M5B 1W8

Not Yet Recruiting

14

Universite de Montreal-Institut de Cardiologie de Montreal (ICM) Montreal Heart Institute (MHI)

Montreal, Quebec, Canada, H1T1C8

Not Yet Recruiting

15

Kyushu University Hospital

Fukuoka, Fukuoka, Japan, 812-8582

Actively Recruiting

16

National Cerebral and Cardiovascular Center

Suita, Osaka, Japan, 564-8565

Not Yet Recruiting

17

Sakakibara Heart Institute

Fuchu-shi, Tokyo, Japan, 183-0003

Not Yet Recruiting

18

Hospital Civil de Guadalajara

Guadalajara, Jalisco, Mexico, 44100

Not Yet Recruiting

Loading map...

Research Team

T

Trial Registration Coordinator

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB) | DecenTrialz